All In Biotech

Drug Trial Radar · NCT06666491

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

A Randomized, Open-label, Multi-center, Interventional Phase 3 Study of the Efficacy and. Safety of Tafenoquine Compared to Primaquine (Both Co-administered With Chloroquine) for the Radical Cure (Relapse Prevention) of Plasmodium Vivax (P. Vivax) Malaria in Indian Participants (Pediatric and Adult Population)

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

May 14, 2027

Study completion May 14, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.

Conditions

  • Malaria, Vivax

Interventions

  • TafenoquineDrug

    A single dose of TQ will be administered orally on Day 1 or Day 2.

  • PrimaquineDrug

    A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).

  • ChloroquineDrug

    A single dose of CQ will be administered orally, daily, on Days 1 to 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visitTime frame: Up to Month 6

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ahmedabad, India · Recruiting

  • GSK Investigational Site

    Bikaner, India · Recruiting

  • GSK Investigational Site

    Kolkata, India · Recruiting

  • GSK Investigational Site

    Mumbai, India · Recruiting

  • GSK Investigational Site

    Surat, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.